Both consolidation and maintenance treatment improve outcomes in primary central nervous system lymphoma: real-world evidence from a tertiary medical center.
Chieh-Lung Cheng, Chang-Tsu Yuan, Wei-Quan Fang, Po-Hao Huang, Hsin-An Hou, Cheng-Hong Tsai, Ming Yao, Wen-Chien Chou, Hwei-Fang Tien
{"title":"Both consolidation and maintenance treatment improve outcomes in primary central nervous system lymphoma: real-world evidence from a tertiary medical center.","authors":"Chieh-Lung Cheng, Chang-Tsu Yuan, Wei-Quan Fang, Po-Hao Huang, Hsin-An Hou, Cheng-Hong Tsai, Ming Yao, Wen-Chien Chou, Hwei-Fang Tien","doi":"10.7150/jca.107661","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Intensive consolidation treatment following high-dose methotrexate (HDMTX)-based chemotherapy is recommended for fit patients with primary central nervous system lymphoma (PCNSL). Otherwise, HDMTX maintenance might be a useful alternative to consolidation approach in certain circumstances. However, the real-world evidence supporting the beneficial role of consolidation treatment or HDMTX maintenance in PCNSL is limited. <b>Methods:</b> We retrospectively analyzed the clinical efficacy and survival impact of consolidation treatment or HDMTX maintenance on patients with PCNSL treated with HDMTX-based induction chemotherapy. <b>Results:</b> A total of 109 patients were evaluated, with a median age at diagnosis being 63 years. Among them, 69 received induction therapy with HDMTX monotherapy and 40 with HDMTX-based polychemotherapies. In total, 67 (61.5%) patients responded to treatment, of whom 56 (51.4%) had complete response. After a 58.9-month median follow-up, overall survival (OS) at 2 and 5 years was 69% and 45%, respectively. The types of induction regimen or frontline rituximab had no survival impact (<i>P</i> = 0.364 and 0.328, respectively). Among the 67 responding patients, 51 received the consolidation/maintenance therapy. Compared to the patients without consolidation/maintenance, those being treated had lower relapse/PD rates (2-year cumulative incidence of relapse/PD, 39.5% vs. 63.6%, <i>P</i> <0.001) and a significantly better OS (5-year survival rate, 63.8% vs. 27.2%, <i>P</i> = 0.016). Multivariate analysis revealed consolidation/maintenance treatment strikingly reduced mortality risk. Notably, HDMTX maintenance had similar efficacy comparable to consolidative whole-brain radiotherapy. Moreover, consolidation treatment was conducive to prolonging remission duration in the later-line settings of patients who responded to subsequent salvage therapies. <b>Conclusion</b>: This real-world evidence provides clear insight that consolidation/maintenance treatment could prolong OS in PCNSL, emphasizing its critical and indispensable role in treating PCNSL.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 6","pages":"1836-1847"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905409/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.107661","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intensive consolidation treatment following high-dose methotrexate (HDMTX)-based chemotherapy is recommended for fit patients with primary central nervous system lymphoma (PCNSL). Otherwise, HDMTX maintenance might be a useful alternative to consolidation approach in certain circumstances. However, the real-world evidence supporting the beneficial role of consolidation treatment or HDMTX maintenance in PCNSL is limited. Methods: We retrospectively analyzed the clinical efficacy and survival impact of consolidation treatment or HDMTX maintenance on patients with PCNSL treated with HDMTX-based induction chemotherapy. Results: A total of 109 patients were evaluated, with a median age at diagnosis being 63 years. Among them, 69 received induction therapy with HDMTX monotherapy and 40 with HDMTX-based polychemotherapies. In total, 67 (61.5%) patients responded to treatment, of whom 56 (51.4%) had complete response. After a 58.9-month median follow-up, overall survival (OS) at 2 and 5 years was 69% and 45%, respectively. The types of induction regimen or frontline rituximab had no survival impact (P = 0.364 and 0.328, respectively). Among the 67 responding patients, 51 received the consolidation/maintenance therapy. Compared to the patients without consolidation/maintenance, those being treated had lower relapse/PD rates (2-year cumulative incidence of relapse/PD, 39.5% vs. 63.6%, P <0.001) and a significantly better OS (5-year survival rate, 63.8% vs. 27.2%, P = 0.016). Multivariate analysis revealed consolidation/maintenance treatment strikingly reduced mortality risk. Notably, HDMTX maintenance had similar efficacy comparable to consolidative whole-brain radiotherapy. Moreover, consolidation treatment was conducive to prolonging remission duration in the later-line settings of patients who responded to subsequent salvage therapies. Conclusion: This real-world evidence provides clear insight that consolidation/maintenance treatment could prolong OS in PCNSL, emphasizing its critical and indispensable role in treating PCNSL.
背景:推荐高剂量甲氨蝶呤(HDMTX)化疗后强化巩固治疗适合原发性中枢神经系统淋巴瘤(PCNSL)患者。否则,在某些情况下,HDMTX维护可能是一种有用的替代整合方法。然而,支持巩固治疗或HDMTX维持在PCNSL中有益作用的现实证据是有限的。方法:回顾性分析以HDMTX为基础的诱导化疗对PCNSL患者进行巩固治疗或维持HDMTX的临床疗效及生存期的影响。结果:共有109例患者被评估,诊断时的中位年龄为63岁。其中69例采用HDMTX单药诱导治疗,40例采用以HDMTX为基础的多药化疗。总共有67例(61.5%)患者对治疗有反应,其中56例(51.4%)患者完全缓解。在58.9个月的中位随访后,2年和5年的总生存率(OS)分别为69%和45%。诱导方案和一线利妥昔单抗的类型对生存率无影响(P分别为0.364和0.328)。在67例应答患者中,51例接受了巩固/维持治疗。与未进行巩固/维持的患者相比,接受治疗的患者复发/PD率较低(2年累积复发/PD发生率,39.5% vs. 63.6%, P P = 0.016)。多变量分析显示,巩固/维持治疗显著降低了死亡风险。值得注意的是,HDMTX维持与巩固性全脑放疗具有相似的疗效。此外,在对后续救助治疗有反应的患者中,巩固治疗有助于延长缓解持续时间。结论:这一现实证据清楚地揭示了巩固/维持治疗可以延长PCNSL的OS,强调了其在治疗PCNSL中的关键和不可或缺的作用。
期刊介绍:
Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.